Table 1 Demographics of patients treated at Stanford Cancer Institute and TCGA
Characteristic | Stanford patients (n = 152) | TCGA (n = 206) |
|---|---|---|
Age at diagnosis | 54.5 (15–90) | 60 (20–90) |
Sex | ||
Male | 74 (48.7%) | 94 (46%) |
Female | 78 (51.3%) | 112 (54%) |
Race or ethnic group | ||
Caucasian | 104 (68%) | N/A |
Hispanic | 22 (14%) | |
Asian | 22 (14%) | |
Other | 4 (3%) | |
Tumor histology | ||
Leiomyosarcoma | 25 | 80 |
Undifferentiated pleomorphic sarcoma | 23 | 44 |
Sarcoma (NOS) | 14 | |
Myxofibrosarcoma | 13 | 17 |
Liposarcoma | 13 | 50 |
Malignant peripheral nerve sheath tumor | 9 | 5 |
Synovial sarcoma | 7 | 10 |
Osteosarcoma | 5 | |
Angiosarcoma | 5 | |
Rhabdomyosarcoma | 3 | |
Ewing’s sarcoma | 3 | |
Chondrosarcoma | 3 | |
Malignant phyllodes tumor | 3 | |
Local or metastatic | ||
Local | 106 (70%) | 89 (43%) |
Locally advanced | 8 (5%) | |
Metastatic | 38 (25%) | 46 (22%) |
Unknown | 71 (34%) | |
Site | ||
Extremity | 46 (30%) | 62 (30%) |
Pelvic | 31 (20%) | 33 (16%) |
Trunk | 15 (10%) | 9 (4%) |
Retroperitoneum | 21 (14%) | 87 (42%) |
Spine | 9 (6%) | 0 |
Breast | 6 (4%) | 0 |
Lungs | 4 (3%) | 2 (1%) |
Other | 10 (7%) | 13 (6%) |
Size (cm) | 11.4 (2–42) | 12.7 (1.2–39.5) |
FNCLCC grade | ||
I | 7 (5%) | 14 (7%) |
II | 23 (15%) | 112 (54%) |
III | 37 (24%) | 80 (39%) |
N/A | 85 (56%) | |
Adjuvant chemotherapy | ||
Yes | 48 (41%) | 47 (23%) |
No | 70 (59%) | 150 (73%) |
N/A | 9 (4%) | |
Adjuvant radiotherapy | ||
Yes | 78 (66%) | 58 (28%) |
No | 37 (31%) | 139 (67%) |
N/A | 9 (4%) | |